Avadel Pharmaceuticals (AVDL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AVDL Stock Forecast

Avadel Pharmaceuticals stock forecast is as follows: an average price target of $17.80 (represents a 52.66% upside from AVDL’s last price of $11.66) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

AVDL Price Target

The average price target for Avadel Pharmaceuticals (AVDL) is $17.80 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $9.00. This represents a potential 52.66% upside from AVDL's last price of $11.66.

AVDL Analyst Ratings

Buy

According to 8 Wall Street analysts, Avadel Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AVDL stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Avadel Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 31, 2024	Francois Brisebois	Oppenheimer	-	-	132.38%	157.29%
May 09, 2024	Oren Livnat	H.C. Wainwright	-	-	66.15%	131.56%
Nov 30, 2022		Jefferies	-	-	24.29%	-5.66%
Aug 11, 2022		Leerink Partners	-	-	68.07%	2.92%
Aug 10, 2022		Needham	-	-	23.12%	-22.81%
Aug 09, 2022	Chris Howerton	Jefferies	-	-	9.44%	-31.39%
May 31, 2022		Needham	-	-	140.00%	-48.54%

Row per page

Go to

The latest Avadel Pharmaceuticals stock forecast, released on Oct 31, 2024 by Francois Brisebois from Oppenheimer, set a price target of $30.00, which represents a 132.38% increase from the stock price at the time of the forecast ($12.91), and a 157.29% increase from AVDL last price ($11.66).

Avadel Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	2
Avg Price Target	$30.00	$30.00	$28.50
Last Closing Price	$11.66	$11.66	$11.66
Upside/Downside	157.29%	157.29%	144.43%

In the current month, the average price target of Avadel Pharmaceuticals stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 157.29% increase as opposed to Avadel Pharmaceuticals's last price of $11.66. This month's average price target is down 0.00% compared to last quarter, and up 5.26% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 31, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 21, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 28, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 11, 2024	Rodman & Renshaw		Buy	Initialise
May 09, 2024	Craig-Hallum	Buy	Buy	Hold
May 09, 2024	H.C. Wainwright	Buy	Buy	Hold
Mar 05, 2024	Piper Sandler	Overweight	Overweight	Hold
Mar 05, 2024	Oppenheimer	Outperform	Outperform	Hold
Mar 05, 2024	Needham	Buy	Buy	Hold
Dec 20, 2023	Needham	Buy	Buy	Hold

Row per page

Go to

Avadel Pharmaceuticals's last stock rating was published by Oppenheimer on Oct 31, 2024. The company gave AVDL a "Outperform" rating, the same as its previous rate.

Avadel Pharmaceuticals Financial Forecast

Avadel Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.50M	$10.09M	$12.24M	$10.99M	$14.23M	$17.55M	$16.44M	$33.29M	$52.51M	$36.22M	$32.73M	$9.18M	$5.14M	$7.36M	$6.76M	$8.09M
Avg Forecast	$104.00M	$97.90M	$86.10M	$74.40M	$82.00M	$76.95M	$69.29M	$58.71M	$52.48M	$48.43M	$37.47M	$25.89M	$18.19M	$5.12M	$361.33K	$7.92M	$9.52M	$9.60M	$10.25M	$10.50M	$13.88M	$28.09M	$889.95K	$33.80M	$36.95M	$16.52M	$4.83M	$5.26M	$4.57M	$5.60M
High Forecast	$112.12M	$105.55M	$92.83M	$80.21M	$88.41M	$82.96M	$74.70M	$61.21M	$56.41M	$48.44M	$37.47M	$25.89M	$19.85M	$5.12M	$389.56K	$7.92M	$9.52M	$9.60M	$10.25M	$10.50M	$13.88M	$33.71M	$1.07M	$40.56M	$44.34M	$19.82M	$5.79M	$6.31M	$5.48M	$6.72M
Low Forecast	$95.40M	$89.80M	$78.98M	$68.25M	$75.22M	$70.59M	$63.56M	$55.87M	$48.36M	$48.43M	$37.47M	$25.89M	$15.53M	$5.12M	$331.45K	$7.92M	$9.52M	$9.60M	$10.25M	$10.50M	$13.88M	$22.47M	$711.96K	$27.04M	$29.56M	$13.21M	$3.86M	$4.21M	$3.65M	$4.48M
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	9	6	4	4	7	4	11	9	12	13	15	19	13	9	14
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.14%	1.27%	1.29%	1.15%	1.39%	1.67%	1.18%	1.19%	59.00%	1.07%	0.89%	0.56%	1.06%	1.40%	1.48%	1.44%

Avadel Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 3 analysts is $5.12M, with a low forecast of $5.12M, and a high forecast of $5.12M. AVDL's average Quarter revenue forecast represents a 242.57% increase compared to the company's last Quarter revenue of $1.50M (Jun 23).

Avadel Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	9	6	4	4	7	4	11	9	12	13	15	19	13	9	14
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-49.54M	$39.92M	$-6.73M	$-7.75M	$-2.88M	$-3.02M	$-9.96M	$-10.98M	$35.55M	$6.55M	$25.78M	$-20.20M	$-9.47M	$762.00K	$-3.88M	$-2.65M
Avg Forecast	$-8.29M	$-7.81M	$-6.87M	$-5.93M	$-6.54M	$-6.14M	$-5.53M	$-4.68M	$-4.19M	$-3.86M	$-2.99M	$-2.07M	$-1.45M	$-408.73K	$-28.82K	$-383.38K	$-11.61M	$-464.96K	$-496.44K	$-508.55K	$-12.81M	$-8.95M	$-43.10K	$18.12M	$29.11M	$-36.36M	$-8.90M	$544.28K	$-2.01M	$-1.84M
High Forecast	$-7.61M	$-7.16M	$-6.30M	$-5.44M	$-6.00M	$-5.63M	$-5.07M	$-4.46M	$-3.86M	$-3.86M	$-2.99M	$-2.07M	$-1.24M	$-408.72K	$-26.43K	$-383.38K	$-9.29M	$-464.96K	$-496.44K	$-508.55K	$-10.25M	$-7.16M	$-34.48K	$21.74M	$34.93M	$-29.09M	$-7.12M	$653.14K	$-1.61M	$-1.47M
Low Forecast	$-8.94M	$-8.42M	$-7.40M	$-6.40M	$-7.05M	$-6.62M	$-5.96M	$-4.88M	$-4.50M	$-3.86M	$-2.99M	$-2.07M	$-1.58M	$-408.73K	$-31.07K	$-383.38K	$-13.93M	$-464.96K	$-496.44K	$-508.55K	$-15.37M	$-10.74M	$-51.72K	$14.50M	$23.29M	$-43.63M	$-10.67M	$435.43K	$-2.41M	$-2.20M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1719.16%	-104.13%	0.58%	16.67%	5.80%	5.94%	0.78%	1.23%	-824.75%	0.36%	0.89%	0.56%	1.06%	1.40%	1.93%	1.44%

3 analysts predict AVDL's average Quarter EBITDA for Jun 23 to be $-28.82K, with a high of $-26.43K and a low of $-31.07K. This is -100.07% lower than Avadel Pharmaceuticals's previous annual EBITDA (Jun 20) of $39.92M.

Avadel Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	9	6	4	4	7	4	11	9	12	13	15	19	13	9	14
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-64.43M	$30.87M	$-865.00K	$-2.74M	$-8.86M	$-8.61M	$-13.02M	$-12.24M	$25.91M	$-6.38M	$11.65M	$-26.64M	$-8.83M	$12.00K	$-4.93M	$-4.02M
Avg Forecast	$28.89M	$25.04M	$16.37M	$8.67M	$23.43M	$13.96M	$7.22M	$-240.75K	$-2.00M	$-7.86M	$-17.23M	$-22.39M	$-27.08M	$-35.81M	$-34.53M	$-16.51M	$-1.49M	$-25.00M	$-15.38M	$-31.73M	$-16.74M	$-9.97M	$1.42B	$-17.63M	$13.15M	$-47.95M	$-8.29M	$8.57K	$-2.55M	$-2.79M
High Forecast	$31.82M	$27.58M	$18.03M	$9.55M	$25.81M	$15.38M	$7.96M	$481.50K	$2.00M	$-7.02M	$-15.38M	$-19.98M	$-22.25M	$-31.96M	$-30.82M	$-16.51M	$-1.19M	$-25.00M	$-15.38M	$-31.73M	$-13.39M	$-7.98M	$1.71B	$-14.10M	$15.78M	$-38.36M	$-6.64M	$10.29K	$-2.04M	$-2.23M
Low Forecast	$25.78M	$22.35M	$14.61M	$7.74M	$20.91M	$12.46M	$6.45M	$-963.00K	$-5.35M	$-8.66M	$-18.98M	$-24.66M	$-32.89M	$-39.45M	$-38.04M	$-16.51M	$-1.79M	$-25.00M	$-15.38M	$-31.73M	$-20.08M	$-11.96M	$1.14B	$-21.15M	$10.52M	$-57.54M	$-9.95M	$6.86K	$-3.07M	$-3.34M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.87%	-1.87%	0.58%	0.11%	0.58%	0.27%	0.78%	1.23%	0.02%	0.36%	0.89%	0.56%	1.06%	1.40%	1.93%	1.44%

Avadel Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-34.53M, with a range of $-38.04M to $-30.82M. AVDL's average Quarter net income forecast represents a -211.84% decrease compared to the company's last Quarter net income of $30.87M (Jun 20).

Avadel Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	9	6	4	4	7	4	11	9	12	13	15	19	13	9	14
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$46.78M	$7.09M	$7.91M	$7.66M	$5.32M	$6.76M	$10.45M	$24.49M	$11.81M	$9.46M	$4.46M	$3.56M	$2.49M	$5.18M	$2.53M	$2.93M
Avg Forecast	$195.23M	$183.77M	$161.62M	$139.66M	$153.93M	$144.46M	$130.07M	$110.21M	$98.51M	$90.92M	$70.33M	$48.61M	$34.14M	$9.62M	$678.28K	$14.76M	$17.75M	$17.90M	$19.11M	$19.58M	$13.43M	$19.95M	$1.66M	$26.15M	$5.04M	$6.40M	$2.34M	$3.70M	$1.31M	$2.03M
High Forecast	$210.47M	$198.13M	$174.25M	$150.57M	$165.96M	$155.74M	$140.23M	$114.90M	$105.89M	$90.93M	$70.33M	$48.61M	$37.26M	$9.62M	$731.26K	$14.76M	$17.75M	$17.90M	$19.11M	$19.58M	$16.12M	$23.94M	$1.99M	$31.38M	$6.05M	$7.68M	$2.81M	$4.44M	$1.57M	$2.43M
Low Forecast	$179.08M	$168.58M	$148.26M	$128.11M	$141.20M	$132.51M	$119.31M	$104.87M	$90.78M	$90.91M	$70.33M	$48.61M	$29.16M	$9.62M	$622.20K	$14.76M	$17.75M	$17.90M	$19.11M	$19.58M	$10.74M	$15.96M	$1.33M	$20.92M	$4.03M	$5.12M	$1.87M	$2.96M	$1.05M	$1.62M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68.97%	0.48%	0.45%	0.43%	0.28%	0.35%	0.78%	1.23%	7.12%	0.36%	0.89%	0.56%	1.06%	1.40%	1.93%	1.44%

Avadel Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $9.62M, based on 3 Wall Street analysts, with a range of $9.62M to $9.62M. The forecast indicates a -79.43% fall compared to AVDL last annual SG&A of $46.78M (Jun 23).

Avadel Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	9	6	4	4	7	4	11	9	12	13	15	19	13	9	14
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.83	$0.57	$-0.02	$-0.07	$-0.24	$-0.23	$-0.35	$-0.32	$0.63	$-0.15	$0.29	$-0.94	$-0.35	-	$-0.20	$-0.17
Avg Forecast	$0.30	$0.26	$0.17	$0.09	$0.24	$0.14	$0.07	$-0.00	$-0.02	$-0.08	$-0.18	$-0.23	$-0.28	$-0.37	$-0.36	$-0.17	$-0.26	$-0.26	$-0.16	$-0.33	$-0.40	$-0.22	$-0.55	$0.39	$0.35	$-0.27	$-0.31	$-0.05	$-0.06	$-0.09
High Forecast	$0.33	$0.29	$0.19	$0.10	$0.27	$0.16	$0.08	$0.01	$0.02	$-0.07	$-0.16	$-0.21	$-0.23	$-0.33	$-0.32	$-0.17	$-0.26	$-0.26	$-0.16	$-0.33	$-0.40	$-0.18	$-0.44	$0.46	$0.42	$-0.22	$-0.25	$-0.04	$-0.05	$-0.07
Low Forecast	$0.27	$0.23	$0.15	$0.08	$0.22	$0.13	$0.07	$-0.01	$-0.06	$-0.09	$-0.20	$-0.26	$-0.34	$-0.41	$-0.39	$-0.17	$-0.26	$-0.26	$-0.16	$-0.33	$-0.40	$-0.26	$-0.66	$0.31	$0.28	$-0.32	$-0.37	$-0.06	$-0.07	$-0.11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.31%	-3.32%	0.08%	0.27%	1.50%	0.70%	0.87%	1.45%	-1.15%	-0.38%	0.83%	3.48%	1.13%	-0.01%	3.33%	1.84%

According to 3 Wall Street analysts, Avadel Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-0.36, with a low estimate of $-0.39 and a high estimate of $-0.32. This represents a -162.91% decrease compared to AVDL previous annual EPS of $0.57 (Jun 20).

Avadel Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVOK	Evoke Pharma	-	-	315.70%	Buy
IRWD	Ironwood Pharmaceuticals	-	-	239.24%	Buy
ASRT	Assertio	-	-	206.38%	Buy
AQST	Aquestive Therapeutics	-	-	124.78%	Buy
DVAX	Dynavax	-	-	97.26%	Buy
AVDL	Avadel Pharmaceuticals	-	-	52.66%	Buy
ANIP	ANI Pharmaceuticals	-	-	38.82%	Buy
ALKS	Alkermes	-	-	26.41%	Hold
NBIX	Neurocrine Biosciences	-	-	17.27%	Buy
ITCI	Intra-Cellular Therapies	-	-	10.28%	Buy
AMRX	Amneal Pharmaceuticals	-	-	7.27%	Buy
DCPH	Deciphera Pharmaceuticals	-	-	2.85%	Hold
LFCR	Lifecore Biomedical	-	-	-11.08%	Buy
AGRX	Agile Therapeutics	-	-	-33.77%	Buy

AVDL Forecast FAQ

Is Avadel Pharmaceuticals a good buy?

Yes, according to 8 Wall Street analysts, Avadel Pharmaceuticals (AVDL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of AVDL's total ratings.

What is AVDL's price target?

Avadel Pharmaceuticals (AVDL) average price target is $17.8 with a range of $9 to $30, implying a 52.66% from its last price of $11.66. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Avadel Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for AVDL stock, the company can go up by 52.66% (from the last price of $11.66 to the average price target of $17.8), up by 157.29% based on the highest stock price target, and down by -22.81% based on the lowest stock price target.

Can Avadel Pharmaceuticals stock reach $20?

AVDL's highest twelve months analyst stock price target of $30 supports the claim that Avadel Pharmaceuticals can reach $20 in the near future.

What is Avadel Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $30 price target for Avadel Pharmaceuticals (AVDL) this month, up 157.29% from its last price of $11.66. Compared to the last 3 and 12 months, the average price target increased by 157.29% and increased by 144.43%, respectively.

What are Avadel Pharmaceuticals's analysts' financial forecasts?

Avadel Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $286.96M (high $307.28M, low $265.24M), average EBITDA is $-22.886M (high $-21.154M, low $-24.507M), average net income is $44.37M (high $49.62M, low $38.85M), average SG&A $538.67M (high $576.82M, low $497.9M), and average EPS is $0.461 (high $0.515, low $0.403). AVDL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $362.4M (high $390.71M, low $332.43M), average EBITDA is $-28.903M (high $-26.513M, low $-31.16M), average net income is $78.97M (high $86.98M, low $70.48M), average SG&A $680.29M (high $733.42M, low $624.03M), and average EPS is $0.82 (high $0.903, low $0.732).

Did the AVDL's actual financial results beat the analysts' financial forecasts?

Based on Avadel Pharmaceuticals's last annual report (Dec 2019), the company's revenue was $59.22M, beating the average analysts forecast of $44.22M by 33.89%. Apple's EBITDA was $-14.34M, beating the average prediction of $-14.277M by 0.44%. The company's net income was $-33.226M, missing the average estimation of $-88.851M by -62.60%. Apple's SG&A was $30.18M, missing the average forecast of $70.02M by -56.89%. Lastly, the company's EPS was $-0.89, missing the average prediction of $-1.15 by -22.61%. In terms of the last quarterly report (Jun 2023), Avadel Pharmaceuticals's revenue was $1.5M, beating the average analysts' forecast of $361.33K by 314.02%. The company's EBITDA was $-49.541M, beating the average prediction of $-28.817K by 171815.88%. Avadel Pharmaceuticals's net income was $-64.432M, beating the average estimation of $-34.53M by 86.60%. The company's SG&A was $46.78M, beating the average forecast of $678.28K by 6796.53%. Lastly, the company's EPS was $-0.83, beating the average prediction of $-0.359 by 131.48%